Lannett Company, Inc. Is Top Strong Buy Upgrade

For today's edition of our upgrade list, we used our website's advanced screening functions to search for UPGRADES to BUY or STRONG BUY with complete forecast and valuation data. They are presented by one-month forecast return. Lannett, Inc. (LCI) is our top-rated upgrade this week and it is a STRONG BUY. Our other picks are BUY-rated stock.

Ticker

Company Name

Market Price

Valuation

Last 12-M Return

1-M Forecast Return

1-Yr Forecast Return

P/E Ratio

Sector Name

LCI

LANNETT INC

21.05

-45.87%

14.90%

1.13%

13.61%

6.48

Medical

AIRM

AIR METHODS CRP

43

5.67%

22.58%

0.53%

6.31%

17.67

Medical

AN

AUTONATION INC

44.53

-18.98%

-6.09%

0.52%

6.26%

10.93

Retail-Wholesale

JASO

JA SOLAR HOLDGS

5.06

-33.02%

-43.15%

0.51%

6.12%

3.35

Oils-Energy

CRL

CHARLES RVR LAB

90

6.10%

27.35%

0.51%

6.12%

19.24

Medical

Lannett, Inc. (LCI) manufactures and distributes pharmaceutical products sold under generic names and historically has manufactured and distributed pharmaceutical products sold under its trade or brand names. In addition, the Company contract manufactures and private labels pharmaceutical products for other companies.

In their most recent earnings report, in February, the company reported a big increase in sales and noted that "Our outlook for the current fiscal year remains strong.  During the quarter, we received several product approvals and continued to make excellent progress."

For the fiscal 2017 second quarter, net sales increased 35% to $170.9 million from $127.1 million for the second quarter of fiscal 2016.  Gross profit was $88.1 million compared with $71.6 million. Operating income was $34.3 million compared with $30.3 million.  Interest expense was $23.3 million compared with $11.8 million for the second quarter of fiscal 2016.  Net income attributable to Lannett was $8.2 million, or $0.22 per diluted share, compared with $13.5 million, or $0.36 per diluted share, for the fiscal 2016 second quarter. 

The company is due to report earnings again at the beginning of May.

Analysts have a price target of @ $29.20/share on this stock with the consensus rating averaging out to a HOLD. That's below our one-year forecast price of $23.91. The stock has bounced up quite a bit from its 52-week low--which was $16.75.

Below is today's data on Lannett, Inc. (LCI):

VALUENGINE RECOMMENDATION: ValuEngine updated its recommendation from BUY to STRONG BUY for LANNETT INC on 2017-03-17. Based on the information we have gathered and our resulting research, we feel that LANNETT INC has the probability to OUTPERFORM average market performance for the next year. The company exhibits ATTRACTIVE P/E Ratio and Sharpe Ratio.

You can download a free copy of detailed report on Lannett, Inc. (LCI) from the link below.

 

ValuEngine Forecast

 

Target
Price*

Expected
Return

1-Month

21.29 1.13%

3-Month

21.04 -0.03%

6-Month

20.83 -1.04%

1-Year

23.91 13.61%

2-Year

18.93 -10.05%

3-Year

15.98 -24.08%

Valuation & Rankings

Valuation

45.87% undervalued

Valuation Rank(?)

95

1-M Forecast Return

1.13%

1-M Forecast Return Rank

99

12-M Return

14.90%

Momentum Rank(?)

52

Sharpe Ratio

0.56

Sharpe Ratio Rank(?)

80

5-Y Avg Annual Return

33.46%

5-Y Avg Annual Rtn Rank

96

Volatility

60.28%

Volatility Rank(?)

28

Expected EPS Growth

8.21%

EPS Growth Rank(?)

37

Market Cap (billions)

0.75

Size Rank

59

Trailing P/E Ratio

6.48

Trailing P/E Rank(?)

98

Forward P/E Ratio

5.99

Forward P/E Ratio Rank

96

PEG Ratio

0.79

PEG Ratio Rank

51

Price/Sales

1.17

Price/Sales Rank(?)

65

Market/Book

1.40

Market/Book Rank(?)

69

Beta

2.37

Beta Rank

8

Alpha

-0.61

Alpha Rank

6

Disclaimer: ValuEngine.com is an independent research ...

more
How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.